The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
Abstract
To address the problem of historically poor results in the treatment of children with advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia (ALL), an intensive chemotherapy regimen was devised using the most effective single agents in high-dose short courses. Treatment commenced with a fractionated schedule of intravenous (IV) cyclophosphamide (300 mg/m2 every 12 hours for six doses) followed immediately by Adriamycin (50 mg/m2) and vincristine (1.5 mg/m2) with combined intrathecal (IT) methotrexate and cytarabine. Predictably, this treatment produced virtually complete disappearance of all tumor and profound myelosuppression. Immediately on hematologic recovery, IV high-dose methotrexate (1,000 mg/m2 over 24 hours) followed by IV cytarabine (400 mg/m2 over the next 48 hours) was administered with leucovorin rescue and repeated IT treatments. The treatment sequence described above is repeated four times, with the dose of cytarabine doubled in succeeding courses, up to 3,200 mg/m2. The entire planned therapy required approximately 24 weeks. Since 1981, we treated a total of 29 children with this approach, 19 of whom had massive unresectable intraabdominal tumor. According to initial extent of disease, 17 were classified as stage III, four as stage IV non-Hodgkin's lymphoma (NHL), and eight as B cell ALL. Eight of the 12 patients with stage IV NHL or B cell ALL had initial involvement of the CNS. Twenty-seven of 29 patients (93%) attained a complete remission. Fourteen of 17 stage III NHL patients remain disease free, for periods ranging from 3+ months to 4 1/2+ years. The actuarial estimate of the proportion of stage III patients remaining disease free at 2 years is 81%. Results in patients with initial involvement of the CNS and/or marrow are much less favorable, with only two of ten patients who attained remission apparently being cured. In addition to stage, the initial serum lactic dehydrogenase (LDH) level emerged as a prognostic indicator, higher levels (over 1,000 IU/L) being associated with the worst prognosis (P less than .05). Major toxicity consisted of severe hematopoietic suppression and febrile episodes associated with neutropenia. We conclude that this treatment is highly effective for advanced-stage Burkitt's tumors in children free of initial CNS involvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Anderson, J. R., Wilson, J. F., Jenkin, R. D. T., Meadows, A. T., Kersey, J., Chilcote, R. R., Coccia, P., Exelby, P., Kushner, J., Siegel, S., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303103081003 · Cited by 327
Clinical pharmacology of cyclophosphamide.
Bagley, C. M., Bostick, F., & DeVita, V. T. (1973) · PubMed · Cited by 314
Cell kinetics in Burkitt lymphoma
Iversen, O. H., Iversen, U., Ziegler, J. L., & Bluming, A. Z. (1974) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(74)90148-0 · Cited by 112
Prognostic factors in Burkitt's lymphoma importance of total tumor burden
MAGRATH, I. T., Lee, Y. J., Anderson, T., Henle, W., Ziegler, J. L., Simon, R. M., & Schein, P. S. (1980) · Cancer · doi:10.1002/1097-0142(19800315)45:6<1507::aid-cncr2820450634>3.0.co;2-d · Cited by 111
Cited by
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Self-citationAdult Burkitt leukemia and lymphoma
Blum, K. A., Lozanski, G., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-02-0405 · Cited by 579
Thomas, D. A., Faderl, S., O'Brien, S., Bueso‐Ramos, C., Cortes, J., Garcia‐Manero, G., Giles, F. J., Verstovsek, S., Wierda, W. G., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21776 · Cited by 566
Non-Hodgkin's Lymphoma in Childhood
Sandlund, J. T., Downing, J. R., & Crist, W. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605093341906 · Cited by 443
Metadata
- Authors
- Murphy, S. B., Bowman, W. P., Abromowitch, M., Mirro, J., Ochs, J., Rivera, G., Pui, C. H., Fairclough, D., & Berard, C. W.
- Venue
- Journal of Clinical Oncology
- Published
- 1986-12
- Volume
- 4
- Issue
- 12
- Pages
- 1732-1739
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1832431868
- Cited by
- 267
- References
- 5
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. https://app.cochat.ai/papers/10.1200/jco.1986.4.12.1732
- The paper
- Murphy, S. B., Bowman, W. P., Abromowitch, M., Mirro, J., Ochs, J., Rivera, G., Pui, C. H., Fairclough, D., & Berard, C. W. (1986). Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1986.4.12.1732
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.